Collegium Pharmaceutical Inc (NASDAQ:COLL) Chairman Michael Thomas Heffernan sold 20,000 shares of the company’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $22.50, for a total transaction of $450,000.00. Following the sale, the chairman now owns 538,987 shares of the company’s stock, valued at approximately $12,127,207.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Thomas Heffernan also recently made the following trade(s):

  • On Wednesday, November 15th, Michael Thomas Heffernan sold 50,000 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $15.53, for a total transaction of $776,500.00.

Shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) traded up $3.17 during trading on Friday, hitting $23.38. 1,660,647 shares of the company’s stock traded hands, compared to its average volume of 559,585. Collegium Pharmaceutical Inc has a 52 week low of $7.37 and a 52 week high of $23.53. The company has a market cap of $761.31 and a PE ratio of -7.87.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. During the same quarter in the prior year, the company earned ($1.13) EPS. The firm’s quarterly revenue was up 2814.6% on a year-over-year basis. research analysts forecast that Collegium Pharmaceutical Inc will post -2.52 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. increased its position in shares of Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at $176,000. Voya Investment Management LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at $125,000. Nationwide Fund Advisors increased its position in shares of Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at $198,000. Institutional investors and hedge funds own 79.98% of the company’s stock.

COLL has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Monday, November 13th. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, November 8th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Jefferies Group reiterated a “buy” rating and set a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, BidaskClub upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Friday, December 29th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $23.33.

TRADEMARK VIOLATION NOTICE: “Michael Thomas Heffernan Sells 20,000 Shares of Collegium Pharmaceutical Inc (COLL) Stock” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2018/01/19/michael-thomas-heffernan-sells-20000-shares-of-collegium-pharmaceutical-inc-coll-stock.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.